Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model

Journal of the Neurological Sciences

Volumn 290, Issue 1-2, 2010, Pages 123-130

  Huang, Rongqin ^a   Ke, Weilun ^a   Liu, Yang ^a   Wu, Dongdong ^b   Feng, Linyin ^b   Jiang, Chen ^a   Pei, Yuanying ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Brain gene therapy; Lactoferrin modified nanoparticles; Multiple dosing administration; Parkinson's disease; Rotenone

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LACTOFERRIN; NANOPARTICLE; NEUROTRANSMITTER; ROTENONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE THERAPY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MONOAMINERGIC SYSTEM; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE;

ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEINS; LACTOFERRIN; MALE; NANOPARTICLES; NEUROTOXINS; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; TREATMENT OUTCOME; UNCOUPLING AGENTS;

EID: 74849115546     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.09.032     Document Type: Article

References (27)

1. Chtarto A., Yang X., Bockstael O., Melas C., Blum D., Lehtonen E., et al. Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Exp Neurol 204 1 (2007) 387-399
2. Schlachetzki F., Zhang Y., Boado R., and Pardridge W.M. Gene therapy of the brain: the trans-vascular approach. Neurology 62 8 (2004) 1275-1281
3. Pardridge W.M. Gene targeting in vivo with pegylated immunoliposomes. Methods Enzymol 373 (2003) 507-528
4. Huang R.Q., Ke W.L., Liu Y., Jiang C., and Pei Y.Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 29 2 (2008) 238-246
5. Deumens R., Blokland A., and Prickaerts J. Modeling Parkinson′s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175 2 (2002) 303-317
6. Liu W.G., Lu G.Q., Li B., and Chen S.D. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson′s disease. Parkinsonism Relat Disord 13 2 (2007) 77-88
7. Huang J., Liu H., Gu W., Yan Z., Xu Z., Yang Y., et al. A delivery strategy for rotenone microspheres in an animal model of Parkinson′s disease. Biomaterials 27 6 (2006) 937-946
8. Samantaray S., Knaryan V.H., Guyton M.K., Matzelle D.D., Ray S.K., and Banik N.L. The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. Neuroscience 146 2 (2007) 741-755
9. Alam M., and Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136 1 (2002) 317-324
10. Sherer T.B., Betarbet R., Kim J.H., and Greenamyre J.T. Selective microglial activation in the rat rotenone model of Parkinson′s disease. Neurosci Lett 341 2 (2003) 87-90
11. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson′s disease. Nat Neurosci 3 12 (2000) 1301-1306
12. Sindhu K.M., Saravanan K.S., and Mohanakumar K.P. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res 1051 1-2 (2005) 25-34
13. Hirsch E.C., Höglinger G., Rousselet E., Breidert T., Parain K., Feger J., et al. Animal models of Parkinson′s disease in rodents induced by toxins: an update. J Neural Transm Suppl 65 (2003) 89-100
14. Hong M., Mukhida K., and Mendez I. GDNF therapy for Parkinson′s disease. Expert Rev Neurother 8 7 (2008) 1125-1139
15. Mochizuki H., Yasuda T., and Mouradian M.M. Advances in gene therapy for movement disorders. Neurotherapeutics 5 2 (2008) 260-269
16. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson′s disease. Science 290 5492 (2000) 767-773
17. Huang R.Q., Qu Y.H., Ke W.L., Zhu J.H., Pei Y.Y., and Jiang C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 21 4 (2007) 1117-1125
18. Cormier A., Morin C., Zini R., Tillement J.P., and Lagrue G. Nicotine protects rat brain mitochondria against experimental injuries. Neuropharmacology 44 5 (2003) 642-652
19. Saravanan K.S., Sindhu K.M., and Mohanakumar K.P. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J Pineal Res 42 3 (2007) 247-253
20. Marella M., Seo B.B., Nakamaru-Ogiso E., Greenamyre J.T., Matsuno-Yagi A., and Yagi T. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson′s disease. PLoS ONE 3 1 (2008) e1433
21. da Cruz M.T., Cardoso A.L., de Almeida L.P., Simões S., and de Lima M.C. Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury. Gene Ther 12 16 (2005) 1242-1252
22. Xia C.F., Boado R.J., Zhang Y., Chu C., and Pardridge W.M. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson′s disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J Gene Med 10 3 (2008) 306-315
23. Faucheux B.A., Nillesse N., Damier P., Spik G., Mouatt-Prigent A., Pierce A., et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci U S A 92 21 (1995) 9603-9607
24. Huang R.Q., Han L., Li J.H., Ren F.L., Ke W.L., Jiang C., and Pei Y.Y. Neuroprotection in a 6-OHDA-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med 11 9 (2009) 754-763
25. Chen X., Liu W., Guoyuan Y., Liu Z., Smith S., Calne D.B., et al. Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson′s disease. Parkinsonism Relat Disord 10 1 (2003) 1-7
26. Zhang Y., and Pardridge W.M. Near complete rescue of experimental Parkinson′s disease with intravenous, non-viral GDNF gene therapy. Pharm Res 26 5 (2009) 1059-1063
27. Pedersen LM, Jacobsen LM, Mollerup S, G jerstad J. Spinal cord long-termpotentiation (LTP) is associated with increased dorsal horn gene expression of IL-1beta, GDNF and iNOS. Eur J Pain in press, doi:10.1016/j.ejpain.2009.05.016.